Beyond the Pill
The move to Value Based Care (VBC) is changing the relationships that pharma has historically had with both payers and providers. The growing chronic disease burden, rise of digital health and commoditization of many drug-disease areas is forcing a rethinking of the underlying pharmaceutical (pharma) business model.
The Medicine-as-a-Service or “Beyond the Pill” paradigm is likely to play a major part in future pharma business models and one of the key differentiators in the marketplace will be the analytics offerings that pharma companies develop with their partners in “owning the disease” across the value chain including drugs, disease/care management platforms, and both patient and clinician engagement.
One of the key drivers shaping the future of pharma analytics is the growing emphasis on cost-effectiveness data for pharma products. The days are gone where minor modifications to molecules will pass muster for providers and payers without demonstration of substantial therapeutic gains. In the future, providers and payers will increasingly demand pharma to provide data to support their needs to contain costs while improving outcomes.